Start here if you're new
what it is
Teleflex sells the single-use medical tools hospitals use in critical care, surgery, and diagnostic procedures.
how it gets paid
Last year Teleflex made $2.0B in revenue.
why it's growing
Revenue grew 250.2% last year. Quarterly revenue reached $569 million, up 29% vs. prior year.
what just happened
Teleflex posted a latest-quarter EPS of $1.93 versus a $0.10 estimate, but the bigger story is still uneven profitability.
At a glance
B+ balance sheet — decent shape, but not bulletproof
25/100 earnings predictability — expect surprises
13.9x trailing p/e — the market's not buying it — or you found a deal
1.3% dividend yield — cash in your pocket every quarter
7.5% return on capital — nothing to write home about
xvary composite: 54/100 — below average
What they do
Teleflex sells the single-use medical tools hospitals use in critical care, surgery, and diagnostic procedures.
Teleflex lives inside the hospital workflow. If your ICU already runs on its catheters, airway tools, and access devices, switching is a paperwork-and-training migraine. That stickiness shows up in a 54.0% gross margin, which is finance-speak for product profit after manufacturing costs, so what: the products still have pricing power even while the income statement looks messy.
How they make money
$2.0B
annual revenue · their business grew +250.2% last year
total revenue
$2.0B
+250.2%
The products that matter
hospital-use medical devices
Medical Device Portfolio
$2.0B revenue · 9.1% net margin
it's the whole company as presented here: $2.0B in annual revenue, but only 9.1 cents of profit from each revenue dollar. That is enough to be viable, not enough to hide execution mistakes.
entire business
businesses being sold
Acute Care, Interventional Urology, and OEM
$2.03B cash proceeds
these are being sold in two transactions for a combined $2.03B in cash, with closing scheduled for the second half of 2026. That number matters because it is the source of both the bull case and the execution risk.
portfolio reset
remaining higher-acuity platform
Retained Critical Care and Surgical Business
post-sale focus
management says the remaining focus will be critical care, vascular access, interventional, and surgical. The data here does not break out revenue for that retained company, which is exactly why you should treat this as a transition story, not a clean compounding story.
what matters next
Key numbers
13.9x
trailing p/e
You are paying 13.9 times earnings for a company Wall Street thinks can recover to $10.5 in forward EPS. Cheap is the point here.
$2.6B
long-term debt
That equals 36% of capital, which means the balance sheet is usable, not pristine. You can survive with it. You cannot ignore it.
$4.0B
2027 revenue est
Sales are expected to double from today's roughly $2.0 billion base, which is why the upside story exists at all.
5.9%
operating margin
Operating margin means profit after running the business but before interest and taxes, so what: Teleflex has very little room for mistakes.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 55 / 100
- long-term debt $2.6B (36% of capital)
- net profit margin 11.8% — keeps 12 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in TFX 3 years ago → it's now worth $4,430.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Teleflex posted a latest-quarter EPS of $1.93 versus a $0.10 estimate, but the bigger story is still uneven profitability.
Quarterly revenue reached $569 million, up 29% vs. prior year. Gross margin held at 54.0%, but the trailing picture is still distorted by large losses and restructuring noise.
$569M
revenue
$1.93
eps
54.0%
gross margin
the number that mattered
The 54.0% gross margin mattered most because it shows the products still earn good money even while reported earnings look broken.
-
in early january, tfx shares shed about 13% of their value soon after the medical device maker announced that ceo and president liam kelly, who was also chairman of the board, had stepped down, effective immediately.
-
board member stuart randle was appointed interim chief executive and president, until a permanent replacement is found, while lead director dr.
-
stephen klasko was named chairman.
-
investors were also clearly disappointed by the company’s preannouncement of less-upbeat revenue results for 2025.teleflex said full-year revenues were likely in a range of $3.27 billion-$3.278 billion, down from its earlier forecast of $3.305 billion-$3.320 billion. the shortfall is being blamed on softer demand for intra-aortic balloon pumps and catheters in the u.s. and asia, and order delays on the oem side. (note that fourth-quarter/full-year results were set to be released after press time.) meanwhile, the company’s strategic business separation is in progress.
-
in december, teleflex entered into agreements to sell its acute care, interventional urology, and oem businesses in two separate transactions, for a combined total of $2.03 billion in cash.the dismantling of these operations is part of a broader strategy laid out earlier last year, which originally considered the split of the business into two distinct publicly traded entities possibly via a spin-off. once the sale transactions close, scheduled for the second half of 2026, teleflex will focus on its core critical-care and high-acuity hospital market segments (vascular access, interventional, and surgical), where it believes growth opportunities are sizable. it will use proceeds from the deals toward stock repurchases, debt repayment, and to enhance growth of the retained business.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is botching the teleflex portfolio reset. The stock already fell about 13% on the CEO exit, and the company is trying to close $2.03B of asset sales while fixing an earnings profile that just swung to a -$4.30 full-year loss.
med
deal execution and timing
Teleflex plans to sell acute care, interventional urology, and OEM for $2.03B in cash, with closing expected in the second half of 2026. Until those deals close, you are underwriting an in-between company.
If the transactions slip or economics change, the expected debt paydown, buybacks, and cleaner strategy all get delayed with them.
med
core demand is showing cracks
Management cut its 2025 revenue view to $3.27B–$3.278B from $3.305B–$3.320B because balloon pumps, catheters, and OEM demand weakened. That is not theoretical risk. It already happened.
This matters because you need the retained business to look sturdier after the separation, not softer before it.
med
leadership credibility gap
The abrupt CEO and chairman departure came while the company was reshaping itself. Interim leadership can keep the lights on. It usually does not get the same valuation multiple as a trusted long-term operator.
The stock's roughly 13% drop on the announcement tells you investors treated this as a trust event, not routine succession planning.
A weaker retained business plus delayed deal proceeds would leave you with the same $2.6B debt load, a lower-margin earnings base, and fewer reasons for the market to rerate the stock.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
second-half 2026 deal closings
Those two transactions are supposed to bring in $2.03B in cash. If timing slips, the whole reset slips with it.
metric
what happens to the $2.03B
Management said debt repayment, buybacks, and reinvestment are on the menu. You want actual allocation, not just a nice menu description.
risk
whether core hospital demand stabilizes
Balloon pumps, catheters, and OEM orders were weak enough to force a revenue cut. A turnaround story gets awkward fast if the remaining business is still decelerating.
trend
margin recovery after the loss year
Quarterly margin hit -45.4% and full-year EPS fell to -$4.30. You need to see those numbers move back toward normal, not just hear that the strategy is cleaner.
Analyst rankings
short-term outlook
average
momentum score 3 — in human-speak, analysts are not seeing a strong near-term signal either way.
risk profile
average
stability score 3 — this is not a bunker stock, but it is not a total rollercoaster either.
chart momentum
average
technical score 3 — the chart is waiting for the operating story to give it a reason to care.
earnings predictability
25 / 100
predictability is weak. Translation: if you own this, expect more earnings noise than you would from a cleaner med-tech name.
source: institutional data
Institutional activity
230 buyers vs. 207 sellers in 3q2025. total institutional holdings: 46.4M shares.
source: institutional data
Price targets
3-5 year target range
$83
$185
$104
current price
$134
target midpoint · +29% from current · 3-5yr high: $240 (+130% · 24% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive